{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:52Z","timestamp":1786118932883,"version":"build-2736575974"},"reference-count":91,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/wco.0b013e3282ff5b8f","type":"journal-article","created":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T03:02:21Z","timestamp":1209610941000},"page":"358-365","source":"Crossref","is-referenced-by-count":28,"title":["Use of intravenous immunoglobulin and plasma exchange in neurological disease"],"prefix":"10.1097","volume":"21","author":[{"given":"Ralf A","family":"Linker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20210206","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"R2-23-20210206","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug insight: the use of intravenous immunoglobulin in neurology: therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"R3-23-20210206","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","article-title":"Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis","volume":"111","author":"Ephrem","year":"2008","journal-title":"Blood"},{"issue":"Suppl","key":"R4-23-20210206","first-page":"43","article-title":"Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide","volume":"19","author":"Flachenecker","year":"1998","journal-title":"Transfus Sci"},{"key":"R5-23-20210206","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ncpneuro0429","article-title":"Shortage of human intravenous immunoglobulin: reasons and possible solutions","volume":"3","author":"Bayry","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"R6-23-20210206","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","article-title":"Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease","volume":"52","author":"Dodel","year":"2002","journal-title":"Ann Neurol"},{"key":"R7-23-20210206","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(06)70447-1","article-title":"Intravenous immunoglobulin for postpolio syndrome: a randomised controlled trial","volume":"5","author":"Gonzalez","year":"2006","journal-title":"Lancet Neurol"},{"key":"R8-23-20210206","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ana.20892","article-title":"Follow-up of four narcolepsy patients treated with intravenous immunoglobulins","volume":"60","author":"Dauvilliers","year":"2006","journal-title":"Ann Neurol"},{"key":"R9-23-20210206","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"R10-23-20210206","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00115-005-2019-1","article-title":"Plasma exchange therapy for steroid unresponsive multiple sclerosis relapses: clinical experience with 16 patients","volume":"77","author":"Schilling","year":"2006","journal-title":"Nervenarzt"},{"key":"R11-23-20210206","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s00415-006-0497-0","article-title":"Plasma exchange therapy for steroid refractory superimposed relapses in secondary progressive multiple sclerosis","volume":"254","author":"Linker","year":"2007","journal-title":"J Neurol"},{"key":"R12-23-20210206","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(05)67102-4","article-title":"Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange","volume":"366","author":"Keegan","year":"2005","journal-title":"Lancet"},{"key":"R13-23-20210206","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","article-title":"The immunopathology of multiple sclerosis: an overview","volume":"17","author":"Lassmann","year":"2007","journal-title":"Brain Pathol"},{"key":"R14-23-20210206","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan","year":"2002","journal-title":"Neurology"},{"key":"R15-23-20210206","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"key":"R16-23-20210206","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"R17-23-20210206","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","article-title":"A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS","volume":"10","author":"Visser","year":"2004","journal-title":"Mult Scler"},{"key":"R18-23-20210206","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","article-title":"Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial","volume":"61","author":"Achiron","year":"2004","journal-title":"Arch Neurol"},{"key":"R19-23-20210206","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.50.2.398","article-title":"Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses","volume":"50","author":"Achiron","year":"1998","journal-title":"Neurology"},{"key":"R20-23-20210206","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1468-1331.2002.00500.x","article-title":"No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment","volume":"9","author":"Lewanska","year":"2002","journal-title":"Eur J Neurol"},{"key":"R21-23-20210206","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.50.5.1273","article-title":"Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis","volume":"50","author":"Sorensen","year":"1998","journal-title":"Neurology"},{"key":"R22-23-20210206","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","article-title":"Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group","volume":"349","author":"Fazekas","year":"1997","journal-title":"Lancet"},{"key":"R24-23-20210206","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/brain\/awh152","article-title":"Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of postpartum relapse","volume":"127","author":"Vukusic","year":"2004","journal-title":"Brain"},{"issue":"Suppl 2","key":"R25-23-20210206","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1177\/135245850000602S05","article-title":"High dose IVIG in the post partum period for prevention of exacerbations in MS","volume":"6","author":"Haas","year":"2000","journal-title":"Mult Scler"},{"key":"R26-23-20210206","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/1352458506075654","article-title":"A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis","volume":"13","author":"Haas","year":"2007","journal-title":"Mult Scler"},{"key":"R27-23-20210206","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00415-004-0537-6","article-title":"Escalating immunotherapy of multiple sclerosis: new aspects and practical application","volume":"251","author":"Rieckmann","year":"2004","journal-title":"J Neurol"},{"key":"R28-23-20210206","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archneur.56.6.661","article-title":"Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases","volume":"56","author":"Stangel","year":"1999","journal-title":"Arch Neurol"},{"key":"R29-23-20210206","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.55.8.1135","article-title":"IV immunoglobulin does not reverse established weakness in MS","volume":"55","author":"Noseworthy","year":"2000","journal-title":"Neurology"},{"key":"R30-23-20210206","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","article-title":"A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis","volume":"56","author":"Noseworthy","year":"2001","journal-title":"Neurology"},{"key":"R31-23-20210206","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1523\/JNEUROSCI.14-10-06230.1994","article-title":"Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis","volume":"14","author":"Miller","year":"1994","journal-title":"J Neurosci"},{"key":"R32-23-20210206","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1212\/01.WNL.0000099074.04539.E0","article-title":"Experience with immunomodulatory treatments in Rasmussen's encephalitis","volume":"61","author":"Granata","year":"2003","journal-title":"Neurology"},{"key":"R33-23-20210206","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/brain\/awg233","article-title":"Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain\u2013Barre syndrome","volume":"126","author":"Odaka","year":"2003","journal-title":"Brain"},{"key":"R34-23-20210206","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1212\/WNL.54.6.1370","article-title":"Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin","volume":"54","author":"Sahlas","year":"2000","journal-title":"Neurology"},{"key":"R35-23-20210206","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1537-2995.2007.01227.x","article-title":"Use of therapeutic plasma exchange in the management of acute hemorrhagic leukoencephalitis: a case report and review of the literature","volume":"47","author":"Ryan","year":"2007","journal-title":"Transfusion"},{"key":"R36-23-20210206","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2004.08.001","article-title":"Effect of immunotherapy in myelitis with atopic diathesis","volume":"227","author":"Murai","year":"2004","journal-title":"J Neurol Sci"},{"key":"R37-23-20210206","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1191\/096120399678841007","article-title":"A study of 20 SLE patients with intravenous immunoglobulin: clinical and serologic response","volume":"8","author":"Levy","year":"1999","journal-title":"Lupus"},{"key":"R38-23-20210206","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","article-title":"Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients","volume":"58","author":"Martinez","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R39-23-20210206","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0140-6736(05)66376-3","article-title":"Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin","volume":"365","author":"Sommer","year":"2005","journal-title":"Lancet"},{"key":"R40-23-20210206","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"key":"R41-23-20210206","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.10279","article-title":"Stiff man syndrome and related conditions","volume":"17","author":"Meinck","year":"2002","journal-title":"Mov Disord"},{"key":"R42-23-20210206","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1526-0968.2001.005001064.x","article-title":"Plasma exchange in stiff-man syndrome","volume":"5","author":"Shariatmadar","year":"2001","journal-title":"Ther Apher"},{"key":"R43-23-20210206","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12028-007-0044-6","article-title":"An unsuccessful trial of immunomodulatory therapy in delayed posthypoxic demyelination","volume":"7","author":"Khot","year":"2007","journal-title":"Neurocrit Care"},{"key":"R44-23-20210206","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1182\/blood.V80.8.1890.bloodjournal8081890","article-title":"Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic","volume":"80","author":"Thompson","year":"1992","journal-title":"Blood"},{"key":"R45-23-20210206","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/10245330600938687","article-title":"Treatment of thrombotic microangiopathies with plasma exchange","volume":"12","author":"Basic-Jukic","year":"2007","journal-title":"Hematology"},{"key":"R46-23-20210206","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain\u2013Barre syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology"},{"key":"R47-23-20210206","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barre syndrome. Dutch Guillain\u2013Barre Study Group","volume":"326","author":"van der Meche","year":"1992","journal-title":"N Engl J Med"},{"key":"R48-23-20210206","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R49-23-20210206","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain\u2013Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days","volume":"71","author":"Raphael","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R50-23-20210206","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain\u2013Barre syndrome: randomised trial","volume":"363","author":"van Koningsveld","year":"2004","journal-title":"Lancet"},{"key":"R51-23-20210206","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain\u2013Barre syndrome: a randomized trial","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics"},{"key":"R52-23-20210206","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.wnl.0000258673.31824.61","article-title":"Intravenous immunoglobulin therapy for Miller\u2013Fisher syndrome","volume":"68","author":"Mori","year":"2007","journal-title":"Neurology"},{"key":"R53-23-20210206","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"N Engl J Med"},{"key":"R54-23-20210206","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, crossover study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"R57-23-20210206","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"key":"R58-23-20210206","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"R59-23-20210206","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","article-title":"Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy","volume":"37","author":"Lee","year":"2007","journal-title":"Muscle Nerve"},{"key":"R60-23-20210206","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/archneur.59.5.751","article-title":"Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy","volume":"59","author":"Sharma","year":"2002","journal-title":"Arch Neurol"},{"key":"R61-23-20210206","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/ard.2002.003996","article-title":"Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis","volume":"62","author":"Levy","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R62-23-20210206","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","article-title":"Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study","volume":"44","author":"Azulay","year":"1994","journal-title":"Neurology"},{"key":"R63-23-20210206","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","article-title":"Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study","volume":"55","author":"Federico","year":"2000","journal-title":"Neurology"},{"key":"R64-23-20210206","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","article-title":"Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study","volume":"124","author":"Leger","year":"2001","journal-title":"Brain"},{"key":"R65-23-20210206","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","article-title":"Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study","volume":"59","author":"van den Berg","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R67-23-20210206","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1468-1331.2006.01142.x","article-title":"Prediction of response to IVIg treatment in patients with lower motor neurone disorders","volume":"13","author":"Strigl-Pill","year":"2006","journal-title":"Eur J Neurol"},{"key":"R68-23-20210206","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.50.5.1480","article-title":"Deterioration of multifocal motor neuropathy after plasma exchange","volume":"50","author":"Carpo","year":"1998","journal-title":"Neurology"},{"key":"R69-23-20210206","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF02444000","article-title":"Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis","volume":"243","author":"Meucci","year":"1996","journal-title":"J Neurol"},{"key":"R70-23-20210206","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ana.410230415","article-title":"Plasmapheresis alleviates neuropathy accompanying IgM antimyelin-associated glycoprotein paraproteinemia","volume":"23","author":"Haas","year":"1988","journal-title":"Ann Neurol"},{"key":"R71-23-20210206","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","article-title":"A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy","volume":"249","author":"Comi","year":"2002","journal-title":"J Neurol"},{"key":"R72-23-20210206","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"Dalakas","year":"1996","journal-title":"Ann Neurol"},{"key":"R74-23-20210206","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archneur.59.5.766","article-title":"Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy","volume":"59","author":"Gorson","year":"2002","journal-title":"Arch Neurol"},{"key":"R75-23-20210206","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"R76-23-20210206","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"key":"R77-23-20210206","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mus.10224","article-title":"Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis","volume":"26","author":"Wolfe","year":"2002","journal-title":"Muscle Nerve"},{"key":"R78-23-20210206","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"R79-23-20210206","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00415-006-0235-7","article-title":"Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial","volume":"254","author":"Trikha","year":"2007","journal-title":"J Neurol"},{"key":"R81-23-20210206","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0303-8467(02)00017-3","article-title":"Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis","volume":"105","author":"Wegner","year":"2002","journal-title":"Clin Neurol Neurosurg"},{"key":"R82-23-20210206","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"key":"R83-23-20210206","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1526-0968.2000.004004287.x","article-title":"Apheresis treatment in Lambert\u2013Eaton myasthenic syndrome","volume":"4","author":"Motomura","year":"2000","journal-title":"Ther Apher"},{"key":"R84-23-20210206","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","article-title":"Plasma exchange and immunosuppressive drug treatment in the Lambert\u2013Eaton myasthenic syndrome","volume":"34","author":"Newsom-Davis","year":"1984","journal-title":"Neurology"},{"key":"R85-23-20210206","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0303-8467(00)00093-7","article-title":"Successful immunoglobulin treatment in a patient with neuromyotonia","volume":"102","author":"Alessi","year":"2000","journal-title":"Clin Neurol Neurosurg"},{"key":"R86-23-20210206","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s004150050419","article-title":"Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin","volume":"246","author":"van den Berg","year":"1999","journal-title":"J Neurol"},{"key":"R87-23-20210206","first-page":"453","article-title":"Plasma exchange in dermatomyositis and polymyositis. Retrospective study of 38 cases of plasma exchange","volume":"140","author":"Herson","year":"1989","journal-title":"Ann Med Interne (Paris)"},{"key":"R88-23-20210206","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N Engl J Med"},{"key":"R89-23-20210206","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"R90-23-20210206","first-page":"29","article-title":"High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels","volume":"10","author":"Gottfried","year":"2000","journal-title":"Eur J Dermatol"},{"key":"R91-23-20210206","first-page":"1979","article-title":"Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis","volume":"137","author":"Breems","year":"1993","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R92-23-20210206","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R93-23-20210206","first-page":"1092","article-title":"Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients","volume":"21","author":"Cherin","year":"1994","journal-title":"J Rheumatol"},{"key":"R94-23-20210206","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"R95-23-20210206","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"R96-23-20210206","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"key":"R97-23-20210206","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2377-7-3","article-title":"Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study","volume":"7","author":"Sparks","year":"2007","journal-title":"BMC Neurol"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WCO.0b013e3282ff5b8f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:04:56Z","timestamp":1786035896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00019052-200806000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e3282ff5b8f","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}